Ivimtech
Daejeon, KR · Founded 2017 · 29 employees on LinkedIn · 3 known investors
Find your way into Ivimtech
IVIM Technology develops intravital microscopy systems, including confocal and two-photon microscopes for in vivo imaging of living organisms, and provides contract research organization (CRO) services for preclinical in vivo imaging. It serves academic and pharmaceutical researchers, with an R&D center in Daejeon.
Also known as IVIM Technology · IVIM Technology, Inc. · 아이빔테크놀로지
Investors · 3
Company profile
researched Aug 2026IVIM Technology (Ivimtech) develops and sells intravital microscopy systems for in vivo imaging of living animals, positioning its offering as an "All-in-One" intravital microscopy platform intended to observe the dynamic behavior of cells inside living organisms for disease pathophysiology research and therapeutic discovery. Its product line spans confocal-only, two-photon, and dual-mode systems: IVM-C3, a confocal system with a 4-wavelength laser and four confocal detectors supporting up to four colors and 3D/4D imaging; IVM-M3, a wavelength-tunable two-photon system with an automated fs-pulse NIR laser and second-harmonic generation capability for deep-tissue and label-free imaging of repeating structures; IVM-CM3, a dual-mode confocal and two-photon system with a tunable laser covering 690-1050 nm; IVM-MS3, a compact all-in-one two-photon system with a maintenance-free fixed 920 nm fs-pulse laser; IVM-CMS3, a compact box-type dual-mode confocal/two-photon system described by the company as its best-selling model; and IVM-FS, an open-format system with a larger stage and modules for animals larger than mice and young rats, such as rats over six weeks old, ferrets and rabbits, supplied with a dark curtain so a dedicated dark room is not required.
Beyond instruments, the company sells consumables and software, including the IVI Tag in vivo labeling products for tracking cells and proteins, in vivo imaging fixation adjuncts for stable long-term imaging of dynamic organs such as brain and pancreas, and an AI-Image Denoiser, a self-supervised learning algorithm for noise reduction in intravital microscopy that the company markets with a two-week free trial and a claimed reduction in data processing time from seven hours to 30 minutes. It also lists imaging technology capabilities such as ultrafast imaging speed, motion compensation, AI noise cancelling and customized system builds.
The company additionally offers contract research (CRO) and research services built around disease and application models, including cell therapy animal models, cancer immunotherapy, Alzheimer's disease, inflammatory bowel disease, and drug delivery in the retina and cornea, along with education and training programs covering mouse handling, imaging training and image processing.
Business model
IVIM Technology sells intravital microscopy instruments, related consumables (labeling kits, chambers, accessories, equipment) and imaging software directly and through an online shop, and complements hardware sales with fee-based research/CRO services, training programs and application support.
Revenue derives from sales of intravital microscope systems and customized configurations, consumables and accessories, software such as the AI-Image Denoiser, and paid research/CRO and training services.
Latest developments
Recent activity highlighted on the company website includes promotion of the AI-Image Denoiser with a free two-week trial, the IVI Tag in vivo labeling line and in vivo imaging fixation adjuncts, and planned presence at the International Vascular Biology Meeting 2026 (Adelaide, September 6-10) and K-BRAIN 2026 (September 6-8, 2026). The Korean-language site also lists an investor relations (IR) section.
▸Full profile — market position, technology, go-to-market, geography
Market position
The company describes itself as a global solution provider of intravital microscopy and characterizes IVM-CMS3 as the most compact and affordable dual-mode intravital confocal and two-photon microscope available; it also positions its systems against conventional fluorescence microscopy on detection efficiency, resolution and contrast.
Stated differentiators include all-in-one, box-type integration of confocal and two-photon imaging in a compact footprint, maintenance-free fixed-wavelength or fully automated tunable femtosecond lasers, motion compensation and ultrafast scanning for live-animal imaging, an AI-based self-supervised denoising algorithm, larger-animal support in the IVM-FS with a dark curtain removing the need for a dedicated dark room, and a combined offering of instruments, in vivo labeling reagents and in-house imaging services.
Technology
The core technology is intravital microscopy in confocal and two-photon (including second-harmonic generation) modalities, integrated into single-box all-in-one platforms. Systems use multi-wavelength lasers and multiple high-sensitivity confocal detectors, tunable femtosecond NIR lasers spanning 690-1050 nm or fixed 920 nm compact fs-pulse lasers, and software-integrated laser control with automation algorithms. Stated capabilities include ultrafast imaging speed, motion compensation for imaging moving organs, and a self-supervised deep-learning AI-Image Denoiser for noise reduction. Supporting reagents include IVI Tag in vivo fluorescent labels and fixation adjuncts for long-term organ imaging.
Go-to-market
The company markets through its multilingual website (English, Korean, Japanese, Chinese), an e-commerce shop, brochures, flyers, newsletters, white papers and publication listings, and through webinars, workshops and exhibitions at scientific conferences such as the International Vascular Biology Meeting 2026 in Adelaide (September 6-10) and the Korean Society for Brain and Neural Sciences K-BRAIN 2026 meeting (September 6-8, 2026). Free trials (for example a two-week AI-Image Denoiser trial) and meeting bookings are used to generate leads. It is also listed as a supplier on the InsideScientific/Scientist.com supplier directory.
Academic and industry life-science researchers performing in vivo imaging in small and larger laboratory animals, including groups working on cell therapy, cancer immunotherapy, neurodegeneration, inflammatory bowel disease and ocular drug delivery; the company is also listed as a supplier within a life-science/drug-discovery supplier marketplace directory.
Geography
Korean-based operations with website localization in English, Korean, Japanese and Chinese, and participation in international scientific meetings including events in Australia and Korea.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 3
launches, deals, and filingsCompany website promotes participation in the International Vascular Biology Meeting 2026, held September 6-10 in Adelaide, Australia.
Korean-language site promotes the Korean Society for Brain and Neural Sciences K-BRAIN 2026 meeting, September 6-8, 2026.
IVIM Technology markets an AI-Image Denoiser, a self-supervised learning algorithm for noise reduction in intravital microscopy, offered with a two-week free trial and a claimed reduction of data processing time from seven hours to 30 minutes.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 6
primary sources listed
- Ivimtechivimtech.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Ivimtech do?
- IVIM Technology builds all-in-one intravital confocal and two-photon microscopes and offers in vivo imaging research services.
- Who are Ivimtech's investors?
- Ivimtech's investors include Atinum Investment Co. Ltd., LB Investment, Premier Partners.
- Where is Ivimtech headquartered?
- Ivimtech is headquartered in Daejeon, KR.